Themes · Biotech

Narrative basket·№2 of the day·As of 2026-07-20

Biotech & Genomics/ №2

Clinical-stage momentum leaders, commercial-franchise anchors, and gene-editing / genomic-diagnostics platforms.

As of 2026-07-20, Biotech & Genomics ranks №2 among themes for that session with a composite score of 62/100 and median member RS of 92.

Composite: 62_/100
Median RS: 92
Breadth > 50dma: 73%
% at Highs: 3%
Accumulation: 27%
$-Vol Δ: -37%

Score history · last 4 sessionsLast 62·Range 62–69

Members_{33 tickers}

Ticker / whyRSTrendHighAccum$Vol

ERASErasca; RAS/MAPK precision oncology

RS 99

50D

ACCUM

-46%$63.9M$118.0M

ORKAOruka; IL-17/23 psoriasis biologics

RS 98

50D

-25%$122.8M$163.8M

LQDALiquidia; Yutrepia PAH launch

RS 98

50D

-54%$78.1M$169.3M

REPLReplimune; RP1 melanoma, PDUFA Aug

RS 98

50D

+33%$47.0M$35.3M

PRAXPraxis; CNS/epilepsy pipeline

RS 98

ACCUM

-62%$71.0M$186.8M

TXG10x; single-cell / spatial genomics

RS 98

50D

-24%$103.0M$136.1M

RVMDRevolution; RAS(ON) inhibitors

RS 98

50D

ACCUM

-20%$458.0M$574.4M

URGNUroGen; bladder-cancer franchise

RS 97

50D

HIGH

ACCUM

-27%$22.6M$30.9M

TWSTTwist; DNA-synthesis platform

RS 97

50D

-55%$81.4M$182.6M

GHGuardant; liquid-biopsy franchise

RS 96

50D

-32%$373.5M$548.3M

CMPSCompass; psilocybin Phase 3 wins

RS 96

0%$65.1M$64.9M

QUREuniQure; Huntington's gene therapy, BLA imminent

RS 96

50D

-57%$42.5M$98.0M

CORTCorcept; relacorilant approved + Cushing's

RS 95

50D

ACCUM

+49%$147.6M$98.9M

PSNLPersonalis; MRD liquid biopsy

RS 95

50D

+123%$161.0M$72.2M

VCYTVeracyte; genomic diagnostics

RS 95

50D

+33%$105.8M$79.8M

KYMRKymera; protein degraders

RS 93

50D

-58%$60.4M$142.4M

TGTXBriumvi anti-CD20 franchise

RS 92

50D

-65%$54.4M$156.2M

MRNAModerna; mRNA oncology pivot

RS 91

50D

-55%$295.3M$655.3M

ABCLAbCellera; antibody platform

RS 85

-34%$36.9M$56.1M

INCYIncyte; Jakafi/Opzelura

RS 82

50D

ACCUM

-34%$145.4M$218.8M

NBIXNeurocrine; Crenessity/Ingrezza

RS 82

50D

ACCUM

-17%$169.1M$205.0M

EXELExelixis; Cabometyx franchise

RS 80

50D

-18%$132.2M$161.8M

VRTXVertex; CF franchise + pipeline

RS 62

50D

-47%$529.4M$1.0B

RYTMRhythm; MC4R genetic obesity

RS 61

50D

ACCUM

-53%$48.8M$103.8M

RAREUltragenyx; UX111 PDUFA Q3

RS 60

50D

-64%$35.8M$98.6M

VKTXViking; dual-agonist obesity

RS 59

50D

-38%$69.5M$112.0M

BEAMBeam; base-editing BLA year-end

RS 42

-24%$72.9M$95.6M

IONSIonis; antisense RNA platform

RS 28

-58%$116.2M$277.7M

CRSPCRISPR; Casgevy commercial ramp

RS 27

-21%$77.4M$97.4M

ALNYAlnylam; RNAi leader

RS 26

-23%$370.7M$483.5M

SRPTSarepta; Elevidys DMD franchise

RS 25

ACCUM

-60%$29.8M$74.8M

INSMInsmed; Brinsupri launch ramp

RS 24

50D

-49%$215.7M$423.5M

NTLAIntellia; CRISPR HAE, rolling BLA

RS 22

-48%$40.8M$78.9M

Loading…

Members33 tickers

Members33 tickers

Members_{33 tickers}

Members_{33 tickers}